## **Health Products Regulatory Authority**

# **Summary of Product Characteristics**

## **1 NAME OF THE MEDICINAL PRODUCT**

Topamax 50 mg film-coated tablets

## **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each tablet contains 50 mg of topiramate.

Excipients with known effect: lactose monohydrate

For the full list of excipients, see section 6.1

#### **3 PHARMACEUTICAL FORM**

Film-coated tablet.

Product imported from Portugal Light yellow, round tablet marked 'TOP' on one side and '50' on the other.

#### **4 CLINICAL PARTICULARS**

As per PA22612/013/002

## **5 PHARMACOLOGICAL PROPERTIES**

As per PA22612/013/002

#### **6 PHARMACEUTICAL PARTICULARS**

## 6.1 List of excipients

#### **Core tablet:**

Lactose monohydrate Pregelatinised maize starch Microcrystalline cellulose Sodium starch glycolate (Type A) Magnesium Stearate

## Film-coating:

OPADRY Yellow<sup>1</sup> Carnauba wax

<sup>1</sup>OPADRY Yellow contains:

Hypromellose Macrogol Polysorbate 80 Titanium dioxide (E171) Iron oxide yellow (E172)

## 6.2 Incompatibilities

Not applicable.

21 June 2022 CRN00CXZ7 Page 1 of 2

#### 6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the blister and outer carton of the product as marketed in the country of origin.

## 6.4 Special precautions for storage

Do not store above 25°C.

Store in the original package in order to protect from moisture.

#### 6.5 Nature and contents of container

Over-labelled outer carton containing blister strips.

Pack size: 60 tablets

## 6.6 Special precautions for disposal

No special requirements.

#### **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

IMED Healthcare Ltd. Unit 625 Kilshane Avenue Northwest Business Park Ballycoolin Dublin 15 Ireland

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA1463/136/003

## 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21st February 2014

## 10 DATE OF REVISION OF THE TEXT

June 2022

21 June 2022 CRN00CXZ7 Page 2 of 2